# Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

Study · id `cardio:ct-nct05350969` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05350969](<https://clinicaltrials.gov/study/NCT05350969>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05350969

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.

## Technical summary

Registry record NCT05350969. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-11 (actual); primary completion 2024-09-26 (actual). Results posted on 2026-08-26.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 294 participants (enrolled count; ClinicalTrials.gov record NCT05350969, source copy `cardio:ctgov-nct05350969-2026-08-26`, retrieved 2026-10-26)
- Started: 2022-07-11 (actual) (ClinicalTrials.gov record NCT05350969, source copy `cardio:ctgov-nct05350969-2026-08-26`, retrieved 2026-10-26)
- Primary completion: 2024-09-26 (actual) (ClinicalTrials.gov record NCT05350969, source copy `cardio:ctgov-nct05350969-2026-08-26`, retrieved 2026-10-26)
- Completion: 2025-03-17 (actual) (ClinicalTrials.gov record NCT05350969, source copy `cardio:ctgov-nct05350969-2026-08-26`, retrieved 2026-10-26)
- Results first posted: 2026-08-26 (ClinicalTrials.gov record NCT05350969, source copy `cardio:ctgov-nct05350969-2026-08-26`, retrieved 2026-10-26)
- Countries: Czechia; Germany; Greece; Hungary; Netherlands; Poland; Spain; United Kingdom (ClinicalTrials.gov record NCT05350969, source copy `cardio:ctgov-nct05350969-2026-08-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05350969-2026-08-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
- Acronym: HF-REVERT
- Condition: Myocardial Infarction, Acute
- Condition: Heart Failure, Left Sided
- Intervention (Drug): CDR132L
- Intervention (Drug): Placebo to CDR132L
- Lead sponsor: Cardior Pharmaceuticals GmbH
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial (`cardio:pubmed-42108271`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 87e11027f3510424e198be302519256265be376dbce4b55b27ddb082a94fdf4c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
